Innova (video game company)

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Monday, November 13, 2023
Sale, EBITDA, Three Months, Acquisition, Safety, CMV, International, Investment, S&M, SDF, Depreciation, Patient, DSMB, Internet, FDA, G&A, KMDA, Data monitoring committee, Eastern Time Zone, Availability, Innova (video game company), FIMI, Table, R, Growth, Nine Months, Coronavirus Scientific Advisory Board, TASE, Immunoglobulin G, Clothing, Pharmaceutical industry, Fine chemical, Security (finance), Video game, Reinsurance, Kamada

“Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.

Key Points: 
  • “Our future prospects were also recently further buoyed by the recent closing of our $60 million private placement with FIMI Opportunity Funds.
  • Financial Highlights for the Three Months Ended September 30, 2023
    Total revenues were $37.9 million in the third quarter of 2023, an 18% increase from the $32.2 million recorded in the third quarter of 2022.
  • S&M costs, for the third quarter of 2023 and 2022, included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Retrieved on: 
Wednesday, August 16, 2023
Loss, International, Table, SDF, Eastern Time Zone, European Medicines Agency, Innova (video game company), G&A, KMDA, Action Replay, EMA, Internet, FIMI, EBITDA, Kamada, Acquisition, Investment, TASE, Immunoglobulin G, Depreciation, Growth, R, Adjustment, FDA, S&M, Second Half, Three Months, FEV1, Fiscal, Video game, Security (finance), Fine chemical, Pharmaceutical industry, Tutoring, Bookkeeping, Cryptocurrency

“Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “Our strong start to 2023 continued in the second quarter, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • Financial Highlights for the Three Months Ended June 30, 2023
    Total revenues were $37.4 million in the second quarter of 2023, a 59% increase from the $23.6 million recorded in the second quarter of 2022.
  • Gross profit and gross margins were $14.4 million and 39%, respectively, in the second quarter of 2023, compared to $7.2 million and 31%, respectively, reported in the second quarter of 2022.
  • Adjusted EBITDA, as detailed in the tables below, was $6.0 million in the second quarter of 2023, as compared to $1.3 million in the second quarter of 2022.

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Retrieved on: 
Wednesday, May 24, 2023
Workforce, International, Increase, Emphysema, General counsel, Table, DSMB, Bank statement, St Saviour's and St Olave's Church of England School, Food, Innova (video game company), G&A, KMDA, Data monitoring committee, Internet, AATD, FIMI, EBITDA, Kamada, Samsung Galaxy Note 5, Acquisition, Patient, Annual report, Investment, TASE, Corporation, Immunoglobulin G, CFO, Depreciation, Growth, AAT, R, Security (finance), FDA, S&M, Three Months, Video game, Pharmaceutical industry, Fine chemical, Insurance

“We are off to an excellent start to 2023, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.

Key Points: 
  • “We are off to an excellent start to 2023, both financially and operationally,” said Amir London, Kamada’s Chief Executive Officer.
  • “As such, we are reiterating our full-year 2023 revenue guidance of $138 million to $146 million and EBITDA guidance of $22 million to $26 million, which would represent profitability growth of over 30% as compared to 2022.
  • During the first quarter of 2023, Kamada conducted a planned workforce downsizing at its Israeli plant, optimizing staff level to its capacity needs.
  • Kamada continues to expect to generate fiscal year 2023 total revenues in the range of $138 million to $146 million.

Kamada Issues 2023 CEO Letter to Shareholders

Retrieved on: 
Wednesday, March 15, 2023
Acquisition, Data monitoring committee, AAT, CSL Behring, Medical Affairs Bureau, Plasma, TASE, St Saviour's and St Olave's Church of England School, KMDA, Immunoglobulin G, Patient, Physician, Food and Drug Administration, FDA, DSMB, Growth, European Medicines Agency, Safety, SDF, Innova (video game company), Food, Letter, Collection, Fine chemical, Cryptocurrency, Pharmaceutical industry, Video game, Takeda, EU, Kamada, EBITDA

The recently completed 2022 year was a transformational period for Kamada as we embarked on a new and exciting chapter in the Company’s evolution.

Key Points: 
  • The recently completed 2022 year was a transformational period for Kamada as we embarked on a new and exciting chapter in the Company’s evolution.
  • Looking ahead, we expect the momentum from 2022 to extend throughout 2023, with profitability to be further increased as compared to the past year.
  • I am pleased to report that we anticipate continued growth in the portfolio's revenues in 2023 and beyond.
  • Importantly, looking past 2023, based on our multiple catalysts, we continue to project annual double-digit growth in revenues and profits in the foreseeable years ahead.

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Retrieved on: 
Wednesday, March 15, 2023
Annual report, Acquisition, Table, Three Months, AAT, Webcast, International, Plasma, Pivotal, TASE, Regulation of tobacco by the U.S. Food and Drug Administration, Health Canada, St Saviour's and St Olave's Church of England School, Depreciation, R, KMDA, Immunoglobulin G, EBITDA, Acceleration, Investment, FDA, DSMB, Globalization, G&A, European Medicines Agency, Growth, Internet, Security (finance), Safety, Innova (video game company), Food, S&M, Video game, Cryptocurrency, Rare-earth element, Pharmaceutical industry, Fine chemical, Reinsurance, Insurance, Takeda, Kamada

“Importantly, we expect the momentum from 2022 to extend throughout 2023, with profitability to be further enhanced.

Key Points: 
  • “Importantly, we expect the momentum from 2022 to extend throughout 2023, with profitability to be further enhanced.
  • As such, we are introducing full-year 2023 revenue guidance of $138 million to $146 million and EBITDA guidance of $22 million to $26 million.
  • Total revenues during the fourth quarter of 2022 included strong sales from the portfolio of four acquired FDA-approved IgG products.
  • Adjusted EBITDA, as detailed in the tables below, was $7.2 million in the fourth quarter of 2022, as compared to ($1.3) million in the fourth quarter of 2021.

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022

Retrieved on: 
Wednesday, November 16, 2022
Growth, Internet, EMA, AAT, State, Eastern Time Zone, Innova (video game company), Kamada, International, Therapy, TASE, SDF, KMDA, Plasma, FDA, Fine chemical

Kamada management will host an investment community conference call on Tuesday, November 22, at 8:30am Eastern Time to discuss these results and answer questions.

Key Points: 
  • Kamada management will host an investment community conference call on Tuesday, November 22, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel) or 1 201-689-8263 (International) and entering the conference identification number: 13734312.
  • The Company has additional four plasma-derived products which are registered in markets outside the U.S.
  • FIMI Opportunity Fund, the leading private equity investor in Israel, is the Companys lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference

Retrieved on: 
Wednesday, October 26, 2022
TASE, Therapy, Company, AAT, NASDAQ, SDF, Growth, Credit, Conference, State, Innova (video game company), GLOBE, KMDA, FDA, Credit Suisse, EMA, Fine chemical

REHOVOT, Israel and HOBOKEN, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 - 10, 2022.

Key Points: 
  • REHOVOT, Israel and HOBOKEN, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 - 10, 2022.
  • Mr. London is scheduled to present at 3:50 p.m. Eastern Time on November 8, 2022.
  • In addition to the presentation, Mr. London will be available for virtual one-on-one investor meetings throughout the conference.
  • Investors that are interested in arranging a meeting should contact their Credit Suisse representative.

Kamada Awarded $22 Million Extension of Canadian Supply Tender

Retrieved on: 
Wednesday, October 19, 2022
U.S. Securities and Exchange Commission, EBS, Therapy, CBS, SEC, Growth, Achievement, Immunoglobulin G, EMA, Innova (video game company), Top of the Form (quiz show), NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, Form 6-K, Annual report, NASDAQ, Commercial, Contract, Geography, TASE, Private Securities Litigation Reform Act, Knowledge, Health Canada, Food, Company, SDF, KMDA, Industry, Emergent, AAT, GLOBE, MB, State, Forward-looking statement, Canadian Blood Services, Emergent BioSolutions, FDA, COVID-19, Pharmaceutical industry, Fine chemical, Kamada

The four commercial products, approved by Health Canada and the U.S. Food and Drug Administration (FDA), were acquired by Kamada in November 2021.

Key Points: 
  • The four commercial products, approved by Health Canada and the U.S. Food and Drug Administration (FDA), were acquired by Kamada in November 2021.
  • CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec.
  • The extension with CBS is for a three-year period, commencing on April 1, 2023, with an option to extend for up to two additional years.
  • This achievement represents the second significant tender we have recently secured, following the new $11.4 million supply agreement won for VARIZIG from an international organization operating principally in Latin America.

Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022

Retrieved on: 
Wednesday, August 10, 2022
FDA, Internet, GLOBE, AAT, Growth, KMDA, Eastern Time Zone, International, Company, State, Kamada, Therapy, Innova (video game company), NASDAQ, SDF, TASE, EMA

Kamada management will host an investment community conference call on Wednesday, August 17, at 8:30am Eastern Time to discuss these results and answer questions.

Key Points: 
  • Kamada management will host an investment community conference call on Wednesday, August 17, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel), or 1 201-689-8263 (International) and entering the conference identification number: 13732049.
  • The Company has additional four plasma-derived products which are registered in markets outside the U.S.
  • FIMI Opportunity Fund, the leading private equity investor in Israel, is the Companys lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

Retrieved on: 
Friday, July 15, 2022
AAT, SDF, Nasdaq, General Confederation of Labour, Lists of action films, Knowledge, Therapy, KMDA, GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Palestinian General Federation of Trade Unions, Risk, Innova (video game company), EMA, Form, Company, Growth, FDA, State, Pharmaceutical industry, Risk management, Beit Kama, Histadrut

The previously disclosed labor strike has ended, and the unionized employees have now returned to work at the Beit Kama production facility.

Key Points: 
  • The previously disclosed labor strike has ended, and the unionized employees have now returned to work at the Beit Kama production facility.
  • The strike had no impact on the availability of the Companys commercial products.
  • The Companys strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market.
  • FIMI Opportunity Fund, the leading private equity investor in Israel, is the Companys lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.